New: Biosimilars strategies introduced.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
December 21, 2018 - Acorda Therapeutics announced the FDA approval of Inbrija (levodopa) inhalation powder, for the intermittent treatment of OFF episodes in people with Parkinson’s disease treated with carbidopa/levodopa.
Download PDF
Return to publications
